Adam Maeder
Stock Analyst at Piper Sandler
(2.95)
# 1,194
Out of 5,182 analysts
102
Total ratings
39.19%
Success rate
1.79%
Average return
Main Sectors:
Top Industries:
Stocks Rated by Adam Maeder
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| RXST RxSight | Maintains: Neutral | $11 → $10 | $7.56 | +32.28% | 4 | Feb 26, 2026 | |
| TCMD Tactile Systems Technology | Maintains: Overweight | $35 → $42 | $25.85 | +62.48% | 6 | Feb 18, 2026 | |
| INSP Inspire Medical Systems | Maintains: Overweight | $165 → $85 | $57.53 | +47.75% | 18 | Feb 12, 2026 | |
| EW Edwards Lifesciences | Reiterates: Overweight | $98 → $100 | $80.99 | +23.48% | 19 | Feb 11, 2026 | |
| RMD ResMed | Maintains: Neutral | $270 → $275 | $227.97 | +20.63% | 5 | Jan 30, 2026 | |
| ISRG Intuitive Surgical | Maintains: Overweight | $610 → $620 | $470.50 | +31.77% | 22 | Jan 23, 2026 | |
| ABT Abbott Laboratories | Maintains: Overweight | $150 → $135 | $96.46 | +39.95% | 4 | Jan 23, 2026 | |
| SGHT Sight Sciences | Upgrades: Overweight | $5 → $9 | $4.07 | +121.13% | 3 | Jan 5, 2026 | |
| NYXH Nyxoah | Reiterates: Overweight | $12 → $9 | $3.32 | +171.08% | 9 | Nov 14, 2025 | |
| NSPR InspireMD | Maintains: Overweight | $4.5 → $4 | $1.35 | +197.04% | 4 | May 12, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Hold | $20 → $21 | $19.39 | +8.33% | 2 | May 22, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Overweight | $7 → $8 | $1.42 | +463.38% | 1 | Mar 6, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $6 → $5 | $2.01 | +148.76% | 2 | Mar 6, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $104 → $99 | $67.50 | +46.67% | 3 | May 5, 2022 |
RxSight
Feb 26, 2026
Maintains: Neutral
Price Target: $11 → $10
Current: $7.56
Upside: +32.28%
Tactile Systems Technology
Feb 18, 2026
Maintains: Overweight
Price Target: $35 → $42
Current: $25.85
Upside: +62.48%
Inspire Medical Systems
Feb 12, 2026
Maintains: Overweight
Price Target: $165 → $85
Current: $57.53
Upside: +47.75%
Edwards Lifesciences
Feb 11, 2026
Reiterates: Overweight
Price Target: $98 → $100
Current: $80.99
Upside: +23.48%
ResMed
Jan 30, 2026
Maintains: Neutral
Price Target: $270 → $275
Current: $227.97
Upside: +20.63%
Intuitive Surgical
Jan 23, 2026
Maintains: Overweight
Price Target: $610 → $620
Current: $470.50
Upside: +31.77%
Abbott Laboratories
Jan 23, 2026
Maintains: Overweight
Price Target: $150 → $135
Current: $96.46
Upside: +39.95%
Sight Sciences
Jan 5, 2026
Upgrades: Overweight
Price Target: $5 → $9
Current: $4.07
Upside: +121.13%
Nyxoah
Nov 14, 2025
Reiterates: Overweight
Price Target: $12 → $9
Current: $3.32
Upside: +171.08%
InspireMD
May 12, 2025
Maintains: Overweight
Price Target: $4.5 → $4
Current: $1.35
Upside: +197.04%
May 22, 2024
Maintains: Hold
Price Target: $20 → $21
Current: $19.39
Upside: +8.33%
Mar 6, 2024
Reiterates: Overweight
Price Target: $7 → $8
Current: $1.42
Upside: +463.38%
Mar 6, 2023
Maintains: Overweight
Price Target: $6 → $5
Current: $2.01
Upside: +148.76%
May 5, 2022
Maintains: Overweight
Price Target: $104 → $99
Current: $67.50
Upside: +46.67%